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Abstract 
Insufficient thyroid hormone (TH) during development results in permanent 
neurological deficits. These deficits are the result of perturbed TH-mediated brain 
development.  Interestingly, insufficient insulin-like growth factor 1 (Igf-1) during 
development results in neurological deficits that are similar to those reported for 
developmental hypothyroidism.  This observation suggests that deficits associated 
with low TH during development may be the result of altered Igf-1 expression in the 
developing brain.  To test this, timed-pregnant mice were treated with thyroid gland 
inhibitors from gestational day 16 (GD16) until postnatal day 21 (P21) to induce a 
hypothyroid state.  A parallel set of untreated timed-pregnant mice were used as 
controls.  Brains from exposed and control pups were collected at P7, P14, P21, and 
P42 and processed for detecting Igf-1 mRNA by RNA isolation and reverse-
transcriptase quantitative real-time PCR.  Trunk blood was collected to measure 
serum thyroxin (T4) by ELISA.  Body weights and total wet brain weights were also 
quantified.  Developmentally hypothyroid mice weighed significantly less at all ages.  
Wet brain weights were significantly smaller in hypothyroid mice at P7, P21, and 
P42.  Igf-1 mRNA levels did not differ significantly in the cortex compared to 
euthyroid controls.  However, Igf-1 mRNA levels were significantly decreased in the 
hippocampus at P7, and in the cerebellum at P14.  Interestingly, Igf-1 mRNA levels 
were increased in hypothyroid mice at P42 in the hippocampus.  Because treatment of 
goitrogens ceased at P21, any differences seen at P42 are the result of permanent TH 
deficit during early development.  Since this result was not reflected in decreased Igf-
1 expression at P42 in any region, it can be assumed that TH has more complex 
  
mechanistic actions than just regulating Igf-1 gene expression.  It is also safe propose 
brain Igf-1 mRNA expression is affected by low serum TH; yet the way Igf-1 gene 
expression is perturbed is regionally and temporally specific.  These findings identify 
a novel, previously unconsidered, mechanism by which thyroid hormone 
insufficiency during development results in neurological deficits.   
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Introduction 
Congenital hypothyroidism (CH) is a condition in which an individual is born 
with a partial or complete lack of thyroid gland function (Brent, 1999).  This deficit of 
thyroid hormone (TH) occurs in approximately 1 in 3500 births, and if untreated, can 
lead to permanent neurological deficits such as low IQ (McMorris et al., 1986).  
Multiple lines of evidence indicate that these permanent neurological deficits are the 
result of decreased amounts of TH during fetal and early post-natal brain development 
(Zoeller and Rovet, 2004).  Interestingly, decreased production of local insulin-like 
growth factor 1 (Igf-1) in the brain during development is reported to produce 
neurological deficits that are similar to that of CH (Beck et al., 1995; Dyer et al., 2016).  
It is therefore reasonable to suggest that perturbed Igf-1 signaling, as a result of low 
thyroid hormone during development, may be responsible for some of the permanent 
cognitive deficits associated in CH. 
The goal of this study is to analyze Igf-1 mRNA expression using quantitative 
real-time reverse-transcription PCR in three well known targets of TH action in the 
developing brain - cortex, hippocampus, and cerebellum - of hypothyroid and euthyroid 
mice.  The working hypothesis is that: low TH during perinatal development reduces 
the temporal expression of Igf-1 mRNA in the cortex, hippocampus, and cerebellum in 
hypothyroid mice when compared to wildtype mice.  The corollary hypothesis is that 
hypothyroidism-induced reductions in brain Igf-1 mRNA results in the permanent 
neurological deficits observed in CH. 
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Literature Review 
Hypothalamic-Pituitary-Thyroid Gland Axis 
1. Overview 
Thyroid hormone production is controlled by the hypothalamic-pituitary-
thyroid gland (HPT) axis (Zoeller et al., 2007).  The HPT axis is conserved throughout 
vertebrates and is well-defined in human and murine models.  The periventricular 
nucleus of the hypothalamus releases thyrotropin-releasing hormone (TRH) into the 
hypophyseal portal system.  Thyrotropes of the anterior pituitary gland respond to TRH 
by releasing thyroid-stimulating hormone (TSH) into the blood stream.  TSH acts on 
the thyroid gland stimulating the production and release of TH. Circulating levels of 
TH levels in serum are tightly controlled by TH acting through negative feedback at 
the level of anterior pituitary gland and hypothalamus. 
The thyroid gland secretes mainly two forms of TH: active receptor ligand 
triiodothyronine (T3) and an inactive prohormone thyroxine (T4) (Zoeller et al., 2007).  
The difference between the active (T3) and inactive (T4) form is the number of iodide 
(I-) anions conjugated to a tyrosine molecule, with four I- on T4 and three I- on T3.  All 
forms of TH are hydrophobic, but require a protein transporter to travel across cell 
membranes.  TH enters target cells where deiodinase enzymes can metabolize TH to 
the active T3 or inactive metabolites. 
Thyroid hormone receptors (TRs) are ligand regulated transcription factors that 
control gene expression.  Two TRs exist in the mammalian genome: thyroid hormone 
receptor-alpha (Thra, TRα) and thyroid hormone receptor-beta (Thrb, TRβ).  TRs bind 
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to areas of DNA called thyroid response elements (TREs).  Also bound to the TRE is 
another receptor, creating either a heterodimer or a homodimer.  A homodimerization 
would be two TRs of the same kind.  A heterodimerization would be either two different 
TRs, or one TR and another complementary receptor like a retinoic X receptor (RXR) 
or a vitamin D3 receptor (VD3R).  Furthermore, complexed receptor cofactors depend 
on the TRs liganded state and can either activate (Co-A) or repress (Co-R) gene 
transcription in the presence or absence of TH, respectively (Zoeller et al., 2007). 
2. Deiodinase Regulation 
The availability of TH to regulate gene expression is controlled locally in cells 
by different deiodinase enzymes.  Deiodinase 2 (DIO2) converts inactive T4 into active 
T3 by removing an iodide (I-) anion through outer ring 5'-deiodination (Zoeller et al., 
2007; Ng et al., 2013).  In the brain, DIO2 is predominately expressed in astrocytes and 
tanycytes (Guadano-Ferraz et al., 1997).  Deiodinase 3 (DIO3) functions to inactivate 
TH by removing the correct I- anion from T4, then converting T4 to reverse-T3 (rT3) 
and T3 to T2 (3,5-diiodo-L-thyronine).  DIO3 is primarily expressed in neurons (Tu et 
al., 1999).  By directly regulating the amount of T3, deiodinases act in a paracrine 
fashion to indirectly regulate TH responsive genes, which has been shown in multiple 
animal models (Freitas et al., 2010).   
4. Receptor Regulation 
 Encoded by genes Thra and Thrb, TRs are cellular homologues of the viral 
oncogene v-erb-A protein product (Weinberger et al., 1986).  Thra transcribes for 
receptors TRα1 and TRα2, and Thrb transcribes TRβ1 and TRβ2.  TRα1, TRβ1, and 
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TRβ2 are ligand binding transcription factors that act as direct regulators of TH 
expression.  TRα2 is non-ligand binding, meaning it cannot bind the necessary ligand 
subunits to regulate TH expression.  TRs are found throughout the CNS in areas such 
as the cortex, hypothalamus, hippocampus, striatum, and cerebellum (Bradley et al., 
1992).  Specifically TRα1 is expressed in developing and adult neurons as well as 
developing Purkinje cells and tanycytes in the cerebellum (Wallis et al., 2010).  TRα1 
covers all T3 binding during fetal brain development while TRβ1 and TRβ2 show 
minimal expression in fetal brain development (Bradley et al., 1992; Yen, 2001).  TRβ 
increases forty-fold from birth to two weeks after birth, and remains high throughout 
life (Yen, 2001).  TRβ1 and –β2 can be found in neurons which feedback on the HPT 
axis to regulate systemic TH release (Flamant et al., 2006). 
GHRH-GH-IGF Axis 
1. Overview 
The hypothalamus releases growth hormone releasing hormone (GHRH) into 
the hypophyseal portal system, which binds GHRH receptors on somatotropes of the 
anterior pituitary gland.  In response, the anterior pituitary gland then releases growth 
hormone (GH), which acts on the liver to produce insulin-like growth factor 1 (Igf-1).  
IGF proteins are small peptides which share homology to insulin and have two 
isoforms: Igf-1 and Igf-2.  Insulin-like growth factors circulate in the plasma attached 
to Igf binding proteins (IGFBPs) and must be released from IGFBP binding to signal.  
Free IGFs bind IGF receptors located on target cells to elicit a response. Serum Igf-1 
is controlled, in-part, through negative feedback at the level of the hypothalamus, 
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inhibiting GHRH release.  Igf-1 and Igf-2 are both needed for normal in utero growth, 
but only Igf-1 is needed for postnatal development (D'Ercole et al., 2002). 
2. Igf-1 Receptors 
Igf-1 receptors are tyrosine kinase receptors similar in structure to insulin 
receptors. There are two types of Igf receptors: Igf-1R and Igf-2R.  Igf-1R binds both 
Igf-1 and Igf-2 but has higher affinity for Igf-1, while Igf-2R only binds Igf-2. Igf-1R 
induces cell signaling through the PI3K-AKT pathway and the Wnt pathways to induce 
cell proliferation (Wang et al., 2010).  Igf-1R reaches peak expression during late 
embryonic stages and decreases to basal levels soon after birth (Feldman et al., 1997).  
Igf-1R expression is similar to that of Igf-1 with expression described in the cortex, 
cerebellum, hippocampus, choroid plexus, and olfactory bulbs (Feldman et al., 1997). 
3. Igf Binding Proteins 
Igf-1 travels throughout the body bound to carrier or binding proteins (IGFBPs).  
These binding proteins provide a plasma reservoir for IGF proteins and slow the 
degradation of IGFs, which in turn increases Igf-1 half-life.  There are six BPs that have 
a high binding affinity for Igf-1: IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-5, 
and IGFBP-6.  Of these IGFBP proteins, IGFBP-2 and IGFBP-4 are the most abundant 
in central nervous system (Dyer et al., 2016). IGFBP-2 and IGFBP-4 expression peaks 
during brain development (Dyer et al., 2016), indicating the importance of tight control 
of Igf-1 action during that time. 
Sites of Thyroid Hormone and Igf-1 Action 
1. Oligodendrocytes and Myelination 
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Mice lacking Igf-1 show deficient myelination throughout the brain. The corpus 
callosum displays decreased myelination and a reduction in thickness disproportionate 
to brain size by 70%.  The anterior commissure was also disproportionately decreased 
to total brain size, and white matter tracts in the spinal cord were decreased (Beck et 
al., 1995).  These effects were hypothesized to be caused by a decreased total number 
of oligodendrocytes throughout the brain; however, myelination was not completely 
abolished, suggesting other regulators of myelination.  Cerebrum cell cultures treated 
with Igf-1 also show increased numbers of oligodendrocytes, increasing in number as 
the dosage increased (Beck et al., 1995). 
Similarly, myelination is reduced in developmentally hypothyroid animals, as 
TH plays an important role in the differentiation, proliferation, and maturation of 
oligodendrocytes throughout development (Rodriguez-Pena, 1999).  Furthermore, 
myelin-basic-protein (MBP), a major component of myelin, is regulated directly by TH 
with a TRE -186 to -169 base pairs from the MBP promoter (Farsetti et al., 1991). 
Oligodendrocytes, which express MBP, are decreased in number under CH conditions 
throughout development, with TH replacement treatment shown to be unsuccessful at 
rescuing cell count at any age (Schoonover et al., 2004).  Collectively, these reports 
indicate that both TH and Igf-1 play an important role in regulating myelination during 
neurodevelopment. 
2. Parvalbumin Neurons 
In Igf-1 KO mice, parvalbumin neurons are decreased disproportionately to 
total brain size by 50%.  Specifically, in the dentate gyrus of the hippocampus, 
parvalbumin neurons were reduced by approximately 35%.  However, the granule cells 
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of the dentate gyrus were reduced in total volume by 59%; which can be partially 
attributed to the loss of parvalbumin neurons. This suggests that Igf-1 is involved in 
the generation of dentate granule neurons (Beck et al., 1995). 
In the developmentally hypothyroid rat brain, a reduction of parvalbumin-
positive interneurons is observed in the neocortex and hippocampus, but no overall 
change in GABAergic neurons was detected (Gilbert et al., 2007).  These observations 
suggest that it is not the numbers of interneurons affected by developmental TH 
insufficiency, rather the phenotypic expression of parvalbumin within these cells.  A 
decrease in parvalbumin-positive interneurons was observed in these regions 
throughout the perinatal period and into adulthood even after restoring a euthyroid 
state.  Furthermore, T4 injections during the early postnatal period rescue parvalbumin 
expression (Gilbert et al., 2007).  Considering these results, Igf-1 and TH are both 
crucial for the proper development of parvalbumin interneurons during brain 
development. 
3. Neurogenesis 
Igf-1 expression is typically found in areas where adult neurogenesis occurs, 
like the hippocampus and cerebellum; however, expression can be detected as early as 
embryonic day 18 (E18) with gradual increase until about postnatal day 20 (P20) 
(D'Ercole et al., 2002).  Sharp increased expression of Igf-1 from P0 to P14 then 
coincides with neuronal proliferation.  After P14 to about P30, a decrease in Igf-1 to 
adult levels corresponds to decreased neuronal proliferation (Bartlett et al., 1991). 
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TH is also crucial for neurogenesis during fetal and postnatal development.  
Decreased TH during early embryogenesis leads to disrupted neuronal migration in 
the cortex and hippocampus, as well as decreased glial cell proliferation in the 
cerebellum (Ausó et al., 2004; Martinez et al., 2011).  More recently, models of 
iodine deficiency during fetal development show enhanced neuronal differentiation in 
the subventricular zone and hippocampus (Kapoor et al., 2012).  During postnatal and 
adult neurogenesis, decreased levels of TH lead to decreased myelination, 
synaptogenesis, and neuronal migration and differentiation (Préau et al., 2015).  The 
effects of decreased TH on neurogenesis are similar to that of decreased Igf-1 levels 
in the same regions of the developing brain.   
TH and Igf-1 Cross Talk 
1. Phenotypic Similarities between Congenital Hypothyroidism and Igf-1 
Deficiency in Animal Models 
A disproportionate decrease in body to brain weight has been seen in Igf-1 
deficient mice, along with an increased number of stillbirths in Igf-1 -/- mice (Beck et 
al., 1995).  These characteristics are similar to the etiology of congenital 
hypothyroidism, which includes low birth weight (Brent, 1999), limited bone growth, 
and Cretinism, a disease characterized by deafness and irreversible mental retardation. 
(Flamant et al., 2006). 
2. Regulation of Systemic Igf-1 by Thyroid Hormone 
It has been shown that thyroid hormone directly effects systemic Igf-1 levels 
and extra-hepatic Igf-1 production, which has been reported in animal models.  
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Decreased levels of TH lead to inhibited levels of circulating GH and thereby reduces 
peripheral Igf-1.  There is also decreased expression of growth hormone receptors 
(GHr) mRNA in hypothyroid rat livers (Chang et al., 2014), potentially leading to 
decreased release of Igf-1.  Interestingly, Igf-1 levels are only restored if T3 or T4 is 
given back (Chang et al., 2014) but not GH alone (Burstein et al., 1979).  These results 
suggest low thyroid hormone disrupts the GH-Igf axis on a systemic level. 
3. Thyroid Hormone Regulation of Locally Produced Igf-1 
Recently it has been hypothesized that thyroid hormone directly regulates Igf-
1 produced in bone, indicating that growth retardation in hypothyroid animals may be 
a result, in part, from reduced Igf-1.  A study focusing on bone acquisition in mice 
supports the notion that prepubertal levels of TH are more important than GH levels 
for local Igf-1 production (Xing et al., 2012).  This study shows a strong positive 
correlation between increasing administration of T3 treatments and rising levels of Igf-
1 in the bone.  It also shows that a natural increase in the amount of circulating T3 
occurs just prior to an Igf-1 increase in bone during early development.  Furthermore, 
Igf-1 transcription was also shown to be directly regulated by a TRE in the IGF-1 gene 
which can be activated by TRα in osteoblasts (Xing et al., 2012). 
In the brain, Kline and colleagues reported a decrease in Igf-1 positive cells in 
the motor cortex of developmentally hypothyroid mice when compared to euthyroid 
mice (Kline, 2016).  Moreover, this study reported that T4 and serum Igf-1 levels were 
positively correlated (Kline, 2016). 
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Together, this evidence suggests that circulating thyroid hormone controls the 
expression of both local brain-derived and hepatic (systemic) Igf-1.  These findings 
bring me to my working hypothesis that: low TH during perinatal development reduces 
local brain-derived Igf-1 mRNA in the cortex, hippocampus, and cerebellum in 
hypothyroid mice when compared to wildtype mice.  The corollary hypothesis is that 
hypothyroidism-induced reductions in brain Igf-1 mRNA result in the permanent 
neurological deficits observed in congenital hypothyroidism. 
Materials and Methods 
Animal Care 
This study used C57BL/6J mice.  This highly inbred strain was supplied by 
Jackson Laboratories.  All experimental procedures were approved by the Minnesota 
State University, Mankato Institutional Animal Care and Use Committee (IACUC). 
Animal Treatment 
Timed pregnant dams were split into two treatment groups: euthyroid (control) 
and hypothyroid.  Hypothyroidism in dams was induced by providing drinking water 
containing 0.01% bovine serum albumin (BSA), 0.02% methimizole (MMI), and 1% 
potassium perchlorate (KClO4).   Control (euthyroid) animals received drinking water 
with 0.01% BSA only.  The treatments were initiated on embryonic day 14.5 (E14.5) 
and continued until postnatal day 21 (P21). Euthyroid pups were weaned from their 
mother at P21 while hypothyroid pups were weaned at P35 to allow for further 
development.  The sample size for each treatment group at each developmental time 
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point assessed was n = 5.  Two samples were lost during processing, leaving an n = 4 
for the cortex and hippocampus at P7. 
Sacrifice and Dissection 
Euthyroid and hypothyroid pups were sacrificed at ages P7, P14, P21, and P42.  
As per protocol, pups were euthanized using CO2 gas followed by decapitation using 
sharp scissors.  Immediately following decapitation trunk blood was collected and 
allowed to coagulate on ice.   The brain was then carefully dissected from the skull and 
total wet brain weight was measured on an analytical scale.  Next, the cerebellum was 
removed from the cerebrum, placed in a 2mL tube, frozen on dry ice, and stored in a -
80oC freezer.  The remaining cerebrum was concomitantly frozen on dry ice and stored 
at -80oC until microdissection could occur. 
Serum Analysis 
Trunk blood was collected at all experimental ages investigated.  Whole blood 
was allowed to coagulate on wet ice for no less than 20 minutes and no longer than one 
hour.  Serum was isolated by centrifuging trunk blood for 10 minutes at eight relative 
centrifugal force (rcf) and stored at -20oC until an enzyme-linked immunosorbent assay 
(ELISA) could be performed to measure circulating hormone levels.  A Human T4 
ELISA Test Kit was used to analyze T4 levels in the serum, following manufacturer 
protocol.  Resulting concentrations were calculated based on assay standards. 
Microdissection for Cortex and Hippocampal Regions 
Frozen cerebral tissue samples were mounted in Optimal Cutting Temperature 
(OCT) Compound and sectioned in the coronal plane at 20 microns until the corpus 
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callosum could be identified by methyl blue staining.  Once reached, the brain was 
removed from the OCT compound, placed in a coronal brain matrix containing 1mm 
intervals, and a slice extending 1mm posterior from the corpus callosum was collected 
at Bregma 1.09mm and Interaural 4.88mm.  Using the Allen-Brain atlas, 
microdissection of the motor cortex included removing tissue inferior to the corpus 
callosum, and tissue lateral to the motor cortex (Figure 1A).  Following cortex 
collection, the brain was then remounted in OCT and the microdissection steps were 
repeated to collect the hippocampus at Bregma -1.43 mm and Interaural 2.36mm 
(Figure 1B).  Cerebral tissue samples were collected for five pups at each age interval.  
Sections were placed in a collection tube and immediately homogenized with 900μl of 
QIAzol Lysis Reagent using a rotor stator homogenizer for 30 to 60 seconds.  The 
processed homogenate was then stored at -80°C until RNA isolation could occur. 
 
 
 
 
 
Figure 1. Coronal sections of the murine brain. Regions outlined in red represent the 
microdissected regions of the motor cortex and corpus callosum (left) and also the hippocampus 
(right).  Regions were identified using the Allen-Brain Atlas.  
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RNA Isolation 
The RNA isolation procedure followed the protocol provided by the Qiagen 
RNeasy Plus Universal Handbook: RNeasy Plus Universal Mini Kit with few 
modifications.  Dissected tissues were combined with 900μl of QIAzol Lysis Reagent 
and homogenized using a rotor stator homogenizer for about 30 seconds until 
homogenous.  Homogenates were then stored at -80°C for no longer than five days 
until RNA processing could continue.  Following a seven-minute room temperature 
incubation after thawing, 100μl gDNA Eliminator Solution was added to the 
homogenate and shaken vigorously for 15 seconds.  180μl of chloroform was added 
and shaken again for 15 seconds.  The homogenate was incubated at room temperature 
for two minutes followed by centrifuging at 12,000 x g for 15 minutes at 4ºC.  The 
aqueous layer was transferred to a new 2ml tube, 600μl of 70% ethanol was added and 
mixed by pipetting.  The sample was then transferred to an RNeasy Mini spin column 
and centrifuged for 15 seconds at 10,000 rpm. An additional on-column DNase 
treatment was completed for cerebellum only.  RNA loaded columns were then wash 
with 700μl of prepared RWT buffer and then twice with 500μl of Buffer RPE. Samples 
were then centrifuged at full speed for one minute to remove any remaining buffer.  
The RNA was eluted from the column by adding 30μl of RNase-free water and 
centrifuged at 10,000rpm for one minute.  For the cerebellum, an additional 30μL 
elution with RNase-free water was completed.  For the cerebral tissues, the initial 30μL 
elution was reused a second time to elute any remaining RNA.  RNA concentration was 
determined using a spectrophotometer and sample quality was determined using 1% 
bleached-agarose gel electrophoresis.  1% household bleach (8.25% sodium 
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hypochlorite) was added to the gel in order to stabilize RNA degradation against 
ribonucleases (Aranda et al., 2012).  Cerebellar samples were then diluted three-fold 
with RNase-free water. RNA samples were stored at -80°C. 
cDNA Synthesis using Reverse Transcription 
Isolated mRNA was reverse transcribed into cDNA according to SuperScript 
IV VILO Master Mix protocol.  Each reaction mixture included 4μL of SuperScript IV 
VILO Master Mix, 1μg of mRNA, and filled to a total of 20μL with RNase-free water.  
The samples were incubated at 25°C for 10 minutes, temperature then increased to 
50°C for 10 minutes, and finally increased again to 85°C for 5 minutes.  This process 
annealed the oligonucleotides to the mRNA, reverse transcribed the RNA, and 
inactivated the reverse transcriptase enzyme. 
Primer Testing 
Igf-1 mRNA primers were used at concentrations of 0.3μM and 0.5μM on 
euthyroid and hypothyroid cDNA samples which were either diluted at a 1:1 ratio with 
water or kept neat.  Primers were amplified with cDNA samples using a standard PCR 
amplification of 40 repetitions of 95°C for 15 minutes, 94°C for 15 seconds, 60°C for 
15 seconds, and 72°C for 30 seconds.  Table 1 shows each tested primers forward and 
reverse sequence, accession number, and band size.   
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 Sequence Accession # Size 
Primer A 
(Harvard 
Bank) 
F: CTGGACCAGAGACCCTTTGC 
R: GGACGGGGACTTCTGAGTCTT 
NM_010512.5 268 bp 
Primer B 
(Ge et al., 
2015) 
F: CAACTCCCAGCTGTGCAATT 
R: GCCAGGTGAACACAAAACT 
NM_001111276.1 165 bp 
Primer C 
(Omazic et al., 
2001) 
F: TGGATGCTCTTCAGTTCGTG 
R: GCAACACTCATCCACAATGC 
NM_010512.5 112 bp 
 
Real Time quantitative-Reverse Transcriptase Polymerase Chain Reaction 
qPCR was conducted using PowerUp Sybr Green PCR mastermix, supplied by 
Thermo Scientific.  Primer efficiency curves were run using ten-fold dilutions for both 
primer sets: Igf-1 and Ppia.  Samples will be plated by region of the brain and then 
further organized by age, for a total of six qPCR plates, two plates per region.  The 
standard curve was a five-fold dilution of one sample of cDNA, which was used on 
each plate to normalize for potential cross-plating differences. 
Statistical Analyses 
1. Body Weight and Total Wet Brain Weight 
 A two-way ANOVA with treatment and age as factors was used to analyze pup 
body weights at P7-P21 (data combined with (Kline, 2016) for a sample size of n = 95).  
A Sidak’s post-hoc t-test corrected for multiple comparisons after the two-way 
ANOVA.  P42 samples were analyzed using an unpaired t-test.  Total wet brain weights 
were analyzed in the same manner as body weights, with a sample size of n = 39.   
Table 1. Igf-1 Primers.  All primers matched to Igf-1 transcript variant one mRNA. Primer A was taken 
from Harvard Bank and has a predicted amplicon length of 268 base pairs. Primer B (Ge et al., 2015) 
and Primer C (Omazic et al., 2001) were found from previous research and have predicted band sizes 
of 165 and 112 base pairs. 
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2.  ELISA Analyses 
 Total serum T4 levels were analyzed using the standard curve method.  
Experimental sample mean absorbance values were then interpolated from 
corresponding standards.  A two-way ANOVA was used to determine statistically 
significant effects of age, treatment, and interaction for samples between P7-P21.  A 
Sidak’s post-hoc t-test was then used to determine significant differences between 
treatment groups at each age.  Concentrations at P42 were analyzed using an unpaired 
t-test test to detect significant differences between treatment groups.  
3.  Quantification of Relative Igf-1 mRNA Levels 
 Igf-1 mRNA quantity was determined via the standard curve method for qRT-
PCR.  An efficiency value was determined using a calibrator sample of cDNA which 
underwent the same processes as experimental cDNA but was serially diluted five-fold 
a total of five times (100ng/μL, 20ng/μL, 4ng/μL, 0.8ng/μL, and 0.16ng/μL).  Relative 
quantities of experimental mRNA could then be calibrated according to quantities 
produced by the standard curve.  The same standard curve dilution set was run on all 
experimental sample plates to normalize for cross-plate analyses.   
 Quantities of relative Igf-1 mRNA were then analyzed using a two-way 
ANOVA to determine significant effects of time, treatment, and interaction between 
ages P7-P21.  A Sidak’s post-hoc t-test was used to correct for multiple comparisons 
to determine any significant differences between treatments.  Igf-1 mRNA levels at age 
P42 were analyzed using an unpaired t-test to determine a significant difference 
between treatment groups.  
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Results 
RNA Quality Testing using Bleach-Agarose Gel Electrophoresis 
No genomic DNA was present along the wells in the cortex (Figure 2A), the 
hippocampus (Figure 2B), or the cerebellum (Figure 2C).  Both 28S and 18S rRNA 
bands were also clearly visible at approximately 1,325 kDa and 750 kDa with no 
smearing, indicating high quality RNA (Figure 2).     
 
 
 
Primer Efficiencies 
All three predicted band sizes of the Igf-1 mRNA primers matched gel results, 
with no difference in amplification between primer concentrations or cDNA dilutions 
(Figure 3).  Based on these observations, primers were used at 0.3μM with undiluted 
cDNA to ensure robust amplification with the least potential for primer associated 
anomalies. 
Figure 2. RNA quality tested using 1% bleach-agarose gel electrophoresis.  The cortex 
(left), hippocampus (middle), and cerebellum (right) all have distinct 28S and 18S banding.  A 1 
Kb plus DNA ladder was used as reference. 
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The selected Igf-1 Primer C (Omazic et al., 2001) and the control primer Ppia 
(cyclophilin-A) were then tested by qRT-PCR for amplification efficiency on a 
euthyroid sample diluted ten-fold five times (100ng/μL, 10ng/μL, 1ng/μL, 0.1ng/μL, 
and 0.01ng/μL).  As shown in Figure 4, the critical threshold of Igf-1 Primer C 
amplification was Ct = 18, while Ct = 12 for Ppia primers. The amplification of all five 
serial dilutions at the same cycle indicates only the target gene was amplified, meaning 
the primers were efficient and specific.   
Figure 3. Igf-1 mRNA transcript variant 1 primer concentration testing.  Standard PCR 
amplification was used with diluted and undiluted, euthyroid and hypothyroid cDNA samples to 
test the most efficient primer-to-cDNA concentration ratio.      
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Body and Brain Weights 
 
A significant effect of age (F(2,74) = 121.2, p < 0.0001) and treatment (F(1,74) = 
80.91, p < 0.0001) was found for body weights.  An interaction was also significant 
(F(3,94) = 18.88, p < 0.0001).  A Sidak’s post-hoc t-test deteremined a significant 
decrease in hypothyroid pup body weights at P7 (t = 2.457, p = 0.0482), P14 (t = 4.325, 
p = 0.0001), and P21 (t = 8.70, p < 0.001).  An unpaired t-test determined a significant 
decrease in hypothyroid pup body weights compared to euthyroid pups at P42 (t = 8.298 
p < 0.0001 (Figure 5A)). 
A significant effect of age (F(2,27) = 62.63, p < 0.0001) and treatment (F(1,27) = 
10.58, p = 0.0031) was observed for wet brain weights (Figure 5B).  Hypothyroid pups 
Figure 4. Igf-1 mRNA and Ppia primer amplification plots.  Primers specifically amplified 
the selected Igf-1 mRNA sequence (top) of all tissue samples.  Experimental control gene 
cyclophilin-A, Ppia (bottom), also showed specific amplification.  
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had significantly lower brain weights when compared to controls at all developmental 
time points except for P14.  These results indicate that hypothyroid pups were 
significantly developmentally stunted in growth compared to euthyroid controls.  More 
importantly, retarded growth size persisted in hypothyroid pups after they were weaned 
from goitrogens.   
 
 
 
 
 
Figure 5. Body weight and total wet brain weight differences 
between developmentally euthyroid and hypothyroid mice.  
Average body weight (top) at sacrifice and average wet brain weight 
(bottom) were analyzed using a two-way ANOVA with a Sidak post-
hoc test.  Body weights were significantly reduced at all ages in 
hypothyroid mice compared to euthyroid.  Wet brain weights were 
also significantly decreased in hypothyroid mice at ages P7, P21, and 
P42. *p<0.05, ***p<0.001, ****p<0.0001 
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Circulating T4 Levels 
A significant effect was found for age (F(2,30) = 38.64, p < 0.0001), treatment 
(F(1,30) = 461.80, p < 0.0001), and an interaction (F(2,30) = 38.11, p < 0.0001).  There 
was a significant reduction of circulating T4 in developmentally hypothyroid pups at 
ages P7, P14, and P21.  At P42, following withdrawal of goitrogens at P21, no 
significant difference between treated and control animals was observed; indicating 
treated pups returned to a euthyroid state (Figure 6).   
 
 
 
Igf-1 Expression Throughout Neurodevelopment 
To understand changes in Igf-1 mRNA levels during brain development, 
relative Igf-1 mRNA levels obtained by qRT-PCR from euthyroid mice were analyzed 
by a two-way ANOVA for ages P7-P42 using brain region and developmental age as 
Figure 6.  Serum T4 levels in developmentally euthyroid and 
hypothyroid mice.  A two-way ANOVA and a Sidak’s post hoc test 
determined a significant reduction in circulating T4 levels at ages P7, 
P14, and P21 in hypothyroid mice.  No significance was found at age 
P42 using an unpaired t test. ****p<0.0001 
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factors.  There was a significant effect of age (F(3,45) = 53.74, p < 0.0001), and region 
(F(3245) = 12.02, p < 0.0001), along with an interaction between the two variables (F(6,45) 
= 6.968, p < 0.0001) meaning the effects of treatment depended on age.  A Sidak post-
hoc test determined that the cortex had significantly greater relative gene expression 
compared to the cerebellum and hippocampus at P14.   
 
 
 
 
Relative Igf-1 mRNA Expression under Euthyroid and Hypothyroid Conditions 
1.  Motor Cortex 
Cortical Igf-1 mRNA levels were analyzed using a two-way ANOVA for ages 
P7-P21 (Figure 8).  A significant effect of age (F(2,23) = 11.61, p = 0.0003) was seen in 
the cortex; yet, there was no significant effect of treatment or an interaction between 
the two.  A Sidak post-hoc t-test indicated no differences in Igf-1 mRNA levels at any 
Figure 7:  Relative Igf-1 mRNA expression under euthyroid conditions 
in the developing motor cortex, hippocampus, and cerebellum.  Igf-1 
gene expression was normalized to Ppia mRNA levels.  2-way ANOVA 
found a significant effect and interaction of age and treatment.  A Sidak 
post-hoc test determined a significant increase in Igf-1 expression in the 
cortex at P14 compared to expression in the hippocampus and cerebellum. 
****p<0.0001.   
// 
// 
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ages investigated in the developing cortex.  No significant difference was observed at 
age P42.   
 
 
 
 
2.  Hippocampus 
In the developing hippocampus, there was a significant effect of age (F(2,23) = 
19.39, p < 0.0001) and a significant interaction (F(2,23) = 8.466, p = 0.0018) between 
age and treatment.  Igf-1 mRNA levels were significantly reduced (t = 3.687, p = 
0.0037) at P7 in hypothyroid mice when compared to euthyroid mice.  Gene expression 
levels between hypothyroid and euthyroid mice did not differ significantly at P14 or 
P21.  At P42, Igf-1 mRNA levels were significantly increased (t = 4.485, p = 0.0028) 
in developmentally hyopthyroid animals compared to developmentally euthyroid.     
Figure 8. Relative Igf-1 expression in the developing cortex during 
neurodevelopment.  A two-way ANOVA and a Sidak’s post-hoc test 
found no significant differences between hypothyroid and euthyroid mice 
at ages P7-P21.  An unpaired t test found no significant difference 
between groups at P42.     
// 
// 
24 
 
 
 
 
 
 
 
 
 
3.  Cerebellum 
In the cerebellum, Igf-1 mRNA levels indicated significant effects of age (F(2,24) 
= 137.3, p < 0.0001), but no effect of treatment or an interaction (Figure 10).  A 
significant decrease in brain Igf-1 levels at P14 was found in developmentally 
hypothyroid mice (t = 2.838, p = 0.0270) when compared to euthyroid controls.  There 
was no significant difference between treatment groups at any other age. 
Figure 9. Relative Igf-1 mRNA expression in the developing 
hippocampus under hypothyroid and euthyroid conditions.  Ages 
P7-P21 were analyzed using a two-way ANOVA and a Sidak’s post-hoc 
test.  Igf-1 mRNA levels were significantly reduced in hypothyroid mice 
at P7.  An unpaired t test at age P42 determined significantly reduced 
Igf-1 gene expression in developmentally euthyroid mice compared to 
hypothyroid mice. **p<0.01 
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Discussion 
Previous studies have shown that low TH reduces the amount of serum Igf-1 
(Burstein et al., 1979; Chang et al., 2014) and tissue-derived Igf-1 (Xing et al., 2012; 
Kline, 2016).  Regulation of serum Igf-1 occurs by way of GH secreted from the 
pituitary gland and its ability to bind hepatic GH receptors, which low TH has been 
shown to decrease (Chang et al., 2014).  In bone, TH, rather than GH, seems to directly 
regulate levels of locally produced Igf-1 (Xing et al., 2012).  However, whether this is 
the case in other extra-hepatic tissues, such as the brain, is yet to be determined.    
Hypothyroidism is defined as low levels of T4 and T3 in serum.  Clinical and 
experimental signs of CH and developmental hypothyroidism include decreased body 
and brain weight.  In the current experiment, goitrogen treatment resulted in 
significantly lower serum T4, body weight, and brain weight; indicating that mice 
Figure 10.  Relative Igf-1 mRNA expression in the developing 
cerebellum.  A two-way ANOVA found a significant effect age, but no 
significant effect of treatment or an interaction for ages P7-P21.  A Sidak 
post-hoc test determined a significant decrease of Igf-1 gene expression at 
P14 in hypothyroid mice when compared to euthyroid controls.  An unpaired 
t test determined no significant difference between groups at P42. *p<0.05 
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treated with goitrogens were indeed overtly hypothyroid.  Serum T4 levels of 
developmentally hypothyroid mice returned to normal at P42 after goitrogens were 
removed at P21; therefore, it is plausible to suggest differences seen at P42 are a 
permanent defect resulting from low TH during development.  This idea is supported 
by the observed decrease in brain and body weights at P42 in developmentally 
hypothyroid mice compared to euthyroid mice.   
 Although our experimental animals exhibit clear signs of overt hypothyroidism, 
it should be noted that tissue TH levels can be regulated locally, uncoupling TH action 
in tissues from circulating T4 levels.  Even with a decreased serum T4, compensatory 
mechanisms such as the type II deiodinase enzyme can increase active T3 in tissues, 
which has been noted for the developing mammalian CNS (Silva and Larsen, 1982).  
However, once animals become overtly hypothyroid, these compensatory mechanisms 
fail to raise tissue T3 to normal levels, resulting in tissue hypothyroidism (Silva and 
Larsen, 1982).  Previous work has also shown a direct correlation between circulating 
amounts of T4 with serum Igf-1 (Kline, 2016) indicating that the incomplete 
compensatory mechanisms for overt developmental hypothyroidism would also most 
likely be unsuccessful at compensating for the consequential decreases of Igf-1.   
 Deficiencies in either Igf-1 or TH lead to similar developmental defects.  
Because Igf-1 knockout models have a high mortality rate, deficiency models of serum 
Igf-1 are considered standard.  Ames and Snell mice are spontaneous mutants that serve 
as experimental models of serum Igf-1 deficiency which also happen to be deficient in 
TH.  These models experience decreased body weight, neuroanatomical defects, and 
cognitive and sensory issues as adults (Carter et al., 2002).  Because the Ames and 
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Snell models exhibit cognitive and neurological deficits when serum Igf-1 is reduced, 
even though brain tissue levels remain unchanged, it is reasonable to suggest that the 
TH deficiency could directly or indirectly be responsible for the neurological deficits 
since both models are deficient in TSH.  Additionally, a liver-specific Igf-1 KO model 
which randomly deletes gene sequences encoding serum Igf-1, reduce serum levels by 
75%; however, tissue levels of local Igf-1 for this model in the heart, brain, kidney, and 
fat show no change in expression even though serum Igf-1 levels are reduced (Carter 
et al., 2002).   
Developmental Hypothyroidism and Igf-1 mRNA Expression 
 TH is critical for normal brain development.  Abnormal brain development in 
response to low TH is thought to be the result of altered gene expression.  Considering 
the report that proposed direct regulation of Igf-1 by thyroid hormone receptors in bone 
and the similar neuroanatomical defects between low TH and low Igf-1 (Xing et al., 
2012), we sought to characterize the effect of low TH in development on locally derived 
Igf-1.  
1. Motor Cortex 
Temporal expression patterns exhibit similar peaks and decreases under both 
treatment conditions.  Levels increase from P7 to peak at P14, followed by a dramatic 
decrease until P42.  Although no statistical difference in cortical Igf-1 mRNA was 
observed between developmentally hypothyroid and euthyroid mice, trends support a 
decreased Igf-1 mRNA expression under hypothyroid conditions.  An increase in 
sample size could potentially provide the power to reach statistical significance.  
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Nonetheless, this observation is inconsistent with other reports that demonstrated 
reduced cortical Igf-1 mRNA (Elder et al., 2000) and Igf-1 positive cells (Kline, 2016).    
Both microglia and oligodendrocytes are important regulators of available Igf-
1 mRNA and protein levels during early postnatal development (Wilkins et al., 2001; 
Ueno et al., 2013).  They are also both targets of TH signaling during brain development 
(Lima et al., 2001; Schoonover et al., 2004).  Highly accumulated in white matter tracts 
like the corpus callosum, microglia produce Igf-1 which leads to neuronal survival 
during development.  When microglia are transfected with Igf-1 siRNA, decreased 
neuronal survival followed decreased Igf-1 mRNA levels (Ueno et al., 2013).   
However, in mice where microglia responses are dysregulated following 
fractalkine receptor Cx3cr1-deficiency, neuronal survival decreases following no 
change in Igf-1 mRNA levels.  Ueno and colleagues found although Igf-1 mRNA levels 
hadn’t changed, the IGF protein inhibitor IGFBP5 was upregulated.  This upregulation 
of the binding protein limits the availability of free IGF-1 protein to activate its receptor 
leading to neuronal apoptosis in the presence of normal Igf-1 mRNA levels.   
Oligodendrocytes could undergo a similar process, which are also heavily 
accumulated near white matter tracts, potentially explaining why there was no 
significant difference seen in Igf-1 mRNA levels between each treatment group.  
Studies focusing on Igf-1 positive cells in the motor cortex found statistically less cells 
in developmentally hypothyroid mice when compared to controls (Kline, 2016), 
suggesting a possible compensation in Igf-1 mRNA production by the remaining Igf-1 
positive cells to restore overall Igf-1 expression.  However, it has yet to be determined 
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if these cell types include microglia, and it is not known if developmental 
hypothyroidism leads to microglial dysregulation.  
Future experiments focusing on IGF-1 protein levels should be conducted 
throughout the cortex to compare mRNA locations and quantities to that of protein 
levels to better understand Igf-1 mechanisms.  Igf-1 positive cells could also be 
identified as a specific cell type to determine if developmental hypothyroidism effects 
the production of Igf-1 mRNA differently in each type.   
2. Hippocampus 
Temporally, we observed Igf-1 mRNA levels in the hippocampus peaked at P7, 
then decreased until P21 when expression reached adult levels measured at P42.  At 
P7, Igf-1 mRNA in the hippocampus of euthyroid mice was significantly higher than 
in hypothyroid mice.  Although Igf-1 mRNA in euthyroid animals decreased, 
expression under hypothyroid conditions peaked at P14 and surpassed euthyroid 
mRNA levels.  Although the higher Igf-1 mRNA level at this age as well as P21 was 
not significant, Igf-1 expression was statistically higher at P42 following 
developmental hypothyroidism. 
These results could point to a temporal shift of Igf-1 expression during 
development.  Under normal conditions, Igf-1 mRNA levels peak early and fall until 
adulthood.  However, under hypothyroid conditions, Igf-1 levels peak until P14 rather 
than P7, and then begins to fall.  This delayed peak in expression could be attributed to 
low T3 availability.  A similar shift in temporal expression in myelination under 
hypothyroid conditions has been previously reported (Rodriguez-Pena et al., 1993).  
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However, whether the delayed expression of Igf-1 is related to the altered myelination 
(or vice versa) remains to be tested. 
More than half of all T3 availability in the brain comes from conversion of T4 
by Dio2 (Bernal, 2015).  Considering this, one could speculate that the ability of Dio2 
activity to increase following developmental hypothyroidism, and moderate the 
changes in brain T3, may also be developmentally regulated.  That is, increased Dio2 
activity may only occur after P7, but prior to P14.  Such a result would increase the 
amount of T3 after P7, thereby delaying peak expression of Igf-1 mRNA.  This delay 
would cause a slowed decrease to adult Igf-1 levels, potentially leading to higher 
amounts of Igf-1 mRNA in hypothyroid mice into adulthood.  Protein levels of Dio2 
as well as mRNA levels of T3 should be examined in neural tissues, including the 
hippocampus, in order to elucidate these discrepancies.   
3. Cerebellum 
Cerebellar expression of Igf-1 at P7 was similar between euthyroid and 
hypothyroid animals, contradicting previous findings of decreased mRNA levels 
during hypothyroidism (Elder et al., 2000).  This inconsistency could be due to 
differences in goitrogen treatment. However, more likely, the difference is due to the 
sensitivity of the assay utilized to quantify Igf-1 levels.  Elder and colleagues used a 
ribonuclease protection assay, which is less sensitive than RT-qRT-PCR at determining 
mRNA levels.   
After P7, a dramatic decrease in Igf-1 expression was seen in both euthyroid 
and hypothyroid conditions, plateauing from P14 to P42.  Hypothyroid pups showed a 
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trending decrease in Igf-1 mRNA levels when compared to euthyroid pups, but was 
only statistically significant at P14. With an overall decreased amount of Igf-1 gene 
expression under hypothyroid conditions, both euthyroid and hypothyroid cerebellums 
followed the same pattern of expression.  Like the cortex, the cerebellum could be quick 
to adjust local T3 availability even in the presence of low serum T4 levels, by increasing 
the amount of DIO2.   
Conclusions 
 Thyroid hormones play a crucial role in neurodevelopment, along with specific 
growth factors such as insulin-like growth factor 1.  Deficiency in either of these two 
hormones lead to similar developmental abnormalities such as decreased body and 
brain size (Beck et al., 1995; Brent, 1999), and mental retardation (Flamant et al., 
2006).  Developmental hypothyroidism is known to cause neurological defects that can 
lead to permanent cognitive deficits if untreated early enough in development (Zoeller 
and Rovet, 2004).  The mechanisms behind these neurological abnormalities following 
low circulating TH levels is yet unknown; however, TH and Igf-1 share many common 
sites of action throughout the developing brain.  The goal of this study was to elucidate 
a potential relationship between circulating TH during early development and 
perturbed locally produced brain Igf-1 mRNA levels.   
 The working hypothesis of this study was that: low TH during perinatal 
development reduces the temporal expression of Igf-1 mRNA in the cortex, 
hippocampus, and cerebellum in hypothyroid mice when compared to wildtype mice.  
The corollary hypothesis was that hypothyroidism-induced reductions in brain Igf-1 
mRNA result in the permanent neurological deficits observed in CH.  
32 
 
 
 
 Overall, the results of this study support this working hypothesis.  In the cortex 
and cerebellum, developmentally hypothyroid mice had decreased amounts of Igf-1 
mRNA, although the difference was not always statistically significant.  In the 
hippocampus, peak Igf-1 mRNA levels shifted to P14 in hypothyroid mice compared 
to P7 under euthyroid conditions.  Because treatment of goitrogens ceased at P21, any 
differences seen at P42 are the result of permanent TH deficit during early 
development.  This evidence is most prominent when comparing overall body weight 
and total wet brain weights, which are both significantly less in hypothyroid mice even 
when serum T4 levels are normal.   
Since this result was not reflected in decreased Igf-1 expression at P42 in any 
region, it can be assumed that TH has more complex mechanistic actions than just 
regulating Igf-1 gene expression.  It is also safe to propose that brain Igf-1 mRNA 
expression is affected by low serum TH; yet the way Igf-1 gene expression is perturbed 
is regionally and temporally specific.  This study has identified a potential novel, 
previously unexplored mechanism, by which low TH during development results in 
neurological deficits.  
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